From the first launch to ongoing market access operational execution, IntegriChain solves some of the most complex and pressing challenges associated with drug commercialization. We deliver pharma’s only comprehensive data, consulting, and business process platform for market access departments, providing the strategy, data, applications, and infrastructure for therapy commercialization.
Solutions overview
IntegriChain delivers the pharmaceutical industry’s largest and only data and business process platform for therapy commercialization and access. Manufacturers rely on our analytics, applications, and managed services to power their operations and harness the value of their channel, patient and payer data.
View all products
IntegriChain provides a complete set of professional services for commercialization and market access execution–from life science strategy and operational consulting to implementation, integration, migrations, and analytics.
Services overview
We help all stakeholders in the pharmaceutical industry drive access with our relentless focus on unifying all of the critical business functions for therapy commercialization and access – contracts & pricing, gross-to-net, channel, and patient services – to unlock strategic payer, provider, pharmacy and patient access insights.
Learn more about our company
Learn more about joining our growing IntegriChain team of data scientists, market access experts, analysts, and consulting professionals – our culture, our purpose, our teams in the US and Pune. Check out our careers or keep in touch for future opportunities.
Careers overview
July 6, 2022
New York, NY, July 6, 2022 – Blue Fin Group, a full-service management consulting firm to the pharmaceutical industry, today announced a new market research study video assessing current and future payer management in oncology by Kerri Fortier, Principal Consultant, and Jonny Clark, PharmD, Consultant (biographies are available here). The quantitative and qualitative data include influences on payer decision-making to prefer drugs in oncology, top barriers and influencers to manage oncolytics, and oncology management expectations in the next three years, including increasing contracting for preference and value-based contracting. The study is based on an award-winning poster on “Payer Perceptions and Practices Regarding Oncology Therapy Management” presented at AMCP Nexus in October 2021.
About Blue Fin Group, an IntegriChain Company Blue Fin Group develops strategies to optimize patient access, commercialization, and gross-to-net to support life sciences manufacturers throughout the product life cycle. Blue Fin Group is a full-service management consulting firm delivering research, strategy, and implementation to help manufacturers align all the elements of marketing, market access, field sales, pharmacy and distribution, and patient services as a seamless commercial strategy that helps optimize patient outcomes. Blue Fin Group has served more than 300 manufacturers–primarily those commercializing their first asset or large global firms with products that span cell and gene therapies, orphan/rare, specialty, primary care, vaccines, biosimilars, and generics. For additional information, visit https://consultbfg.com/ or follow on Twitter and LinkedIn.
For Media Inquiries: Contact Cynthia Keveney at ckeveney@consultbfg.com
Register Now
Webinars & Resources
See List
